Drug intelligence / Profile preview

K-161

Development stage: Phase 3
Lead developer: Kowa Research Institute
Modality: Small Molecules
Administration: Ophthalmic

Overview

K-161 is a small molecule drug developed by Kowa for the treatment of dry eye disease. It is formulated as an ophthalmic solution and has reached Phase 3 clinical trials in the United States for moderate to severe dry eye disease. The precise mechanism of action remains undefined, but it is classified under therapies for eye disorders. Clinical studies have focused on its efficacy and safety in both environmental and controlled adverse environmental settings.

Other names: K 161K161K-161

Beyond the preview

Go deeper on K-161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K-161.

Explore the full profile